Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...

Spinal cord lesions are more commonly seen in progressive forms of multiple sclerosis, and they can result in an increased risk of disability. In relapsing-remitting MS, which 80 to 85 percent of ...

Construction formally began today [Oct. 23] on the hotel that will anchor development of the new Crossroads District between the Mississippi State University campus and the city’s Cotton District.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.